Compounds

US10130633B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Kai Thede · Leverkusen, DE
• William Scott · Guilford, US
• Eckhard Bender · Langenfeld, DE
• Stefan Golz · Wetter (Ruhr), DE
• Andrea Hägebarth · Berlin, DE
• Philip Lienau · Berlin, DE
• Florian Puehler · Wellesley, US
• Daniel BASTING
• Dirk Schneider · Wuppertal, DE
• Manfred Möwes · Berlin, DE
• Anja Richter · Berlin, DE
• Ludwig Zorn · Berlin, DE
• Ningshu Liu · Berlin, DE
• Ursula Mönning · Mölln, DE
• Franziska SIEGEL · Cambridge, US

Key dates

• Filing date: Mar 17, 2014
• Grant date: Nov 20, 2018
• Expiry date: Mar 17, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/08
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to substituted N-(phenyl-heteroaryl)-3-acetylamino-benzamides and N-[3-(acetylamino)phenyl]-phenyl-heteroaryl-carboxamides of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease such as cancer, wherein i.a.: LA represents an optionally substituted methylene or ethylene group; LB represents —N(H)—C(═O)— or —C(═O)—N(H)—; R1 represents an optionally substituted 5- to 8-membered heterocycloalkyl, 4- to 10-membered heterocycloalkenyl, aryl, heteroaryl or —N(R7)(Ci-C6-alkyl) group; R2 represents an optionally substituted 5- or 6-membered heteroaryl group; R3 represents an optionally substituted phenyl group.